Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

NCT00839163 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

613

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thrombosis
Deep Vein Thrombosis

Interventions

DRUG: Xarelto (Rivaroxaban, BAY59-7939)
DRUG: Xarelto (Rivaroxaban, BAY59-7939)
DRUG: Xarelto (Rivaroxaban, BAY59-7939)
DRUG: Xarelto (Rivaroxaban, BAY59-7939)
DRUG: Enoxaparin/Vitamin K-Antagonist

Sponsor

Bayer